Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUPAT-10: Neoadjuvant GEM + nab-paclitaxel for biologically borderline-resectable pancreatic cancer
jRCT1041230068Phase 2Recruiting
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic cancer (PC). Primary endpoint: 2-year overall survival. Started Aug 2023; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT1041230068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230068.